Identification of apolipoprotein A-II in cerebrospinal fluid of pediatric brain tumor patients by protein expression profiling.
暂无分享,去创建一个
M. D. Den Boer | R. Pieters | J. Kros | P. S. Sillevis Smitt | R. V. van Schaik | R. Reddingius | J. M. de Bont | M. Passier | J. Jansen | Theo H Luider | M. D. den Boer
[1] J. Kassubek,et al. Isolated blood–cerebrospinal fluid barrier dysfunction: prevalence and associated diseases , 2005, Journal of Neurology.
[2] D. Kletsas,et al. Differential effects of clusterin/apolipoprotein J on cellular growth and survival. , 2005, Free radical biology & medicine.
[3] William E Grizzle,et al. Serum levels of an isoform of apolipoprotein A-II as a potential marker for prostate cancer. , 2005, Clinical cancer research : an official journal of the American Association for Cancer Research.
[4] Tian-Li Wang,et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. , 2005, Cancer research.
[5] R W Veltri,et al. Proteomic analysis of dunning prostate cancer cell lines with variable metastatic potential using SELDI‐TOF , 2004, The Prostate.
[6] S. Mok,et al. Protein profiling of cervical cancer by protein-biochips: proteomic scoring to discriminate cervical cancer from normal cervix. , 2004, Cancer letters.
[7] V. Schumaker,et al. Sequence of horse (Equus caballus) apoA-II. Another example of a dimer forming apolipoprotein. , 2004, Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology.
[8] D. Morton,et al. Detection of Differentially Expressed Proteins in Early‐Stage Melanoma Patients Using SELDI‐TOF Mass Spectrometry , 2004, Annals of the New York Academy of Sciences.
[9] F. Blanco-Vaca,et al. Apolipoprotein A-II, genetic variation on chromosome 1q21-q24, and disease susceptibility , 2004, Current opinion in lipidology.
[10] T. Veenstra,et al. Organic solvent extraction of proteins and peptides from serum as an effective sample preparation for detection and identification of biomarkers by mass spectrometry , 2004, Proteomics.
[11] D. Chan,et al. Serum Diagnosis of Pancreatic Adenocarcinoma Using Surface-Enhanced Laser Desorption and Ionization Mass Spectrometry , 2004, Clinical Cancer Research.
[12] T. Kang,et al. Pattern analysis of serum proteome distinguishes renal cell carcinoma from other urologic diseases and healthy persons , 2003, Proteomics.
[13] D. Hochstrasser,et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease , 2003, Proteomics.
[14] Rob Pieters,et al. Identification of Tumor‐Related Proteins by Proteomic Analysis of Cerebrospinal Fluid from Patients with Primary Brain Tumors , 2003, Journal of neuropathology and experimental neurology.
[15] J. Roboz,et al. Putative protein markers in the sera of men with prostatic neoplasms , 2003, BJU international.
[16] J. Liepnieks,et al. Hereditary systemic amyloidosis associated with a new apolipoprotein AII stop codon mutation Stop78Arg. , 2003, Kidney international.
[17] T. Zhukov,et al. Discovery of distinct protein profiles specific for lung tumors and pre-malignant lung lesions by SELDI mass spectrometry. , 2003, Lung cancer.
[18] R. Nelson,et al. Novel mass spectrometric immunoassays for the rapid structural characterization of plasma apolipoproteins Published, JLR Papers in Press, December 1, 2002. DOI 10.1194/jlr.D200034-JLR200 , 2003, Journal of Lipid Research.
[19] F. Vizoso,et al. Apolipoprotein D Expression in Retinoblastoma , 2003, Ophthalmic Research.
[20] J. Fruchart,et al. Apolipoprotein A-II, HDL metabolism and atherosclerosis. , 2002, Atherosclerosis.
[21] P. Bondarenko,et al. MALDI- and ESI-MS of the HDL apolipoproteins; new isoforms of apoA-I, II , 2002 .
[22] L. Deterding,et al. Separation and characterization of human high‐density apolipoproteins using a nonaqueous modifier in capillary electrophoresis‐mass spectrometry , 2002, Electrophoresis.
[23] L. Liotta,et al. Proteomic Patterns of Nipple Aspirate Fluids Obtained by SELDI-TOF: Potential for New Biomarkers to Aid in the Diagnosis of Breast Cancer , 2002, Disease markers.
[24] N. Ertel,et al. ProteinChip technology: a new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. , 2002, Journal of proteome research.
[25] K. Lillemoe,et al. Identification of hepatocarcinoma-intestine-pancreas/pancreatitis-associated protein I as a biomarker for pancreatic ductal adenocarcinoma by protein biochip technology. , 2002, Cancer research.
[26] D. Brat,et al. Differential Expression between Pilocytic and Anaplastic Astrocytomas: Identification of Apolipoprotein D as a Marker for Low‐Grade, Non‐Infiltrating Primary CNS Neoplasms , 2002, Journal of neuropathology and experimental neurology.
[27] M. Savolainen,et al. Apolipoprotein E and colon cancer. Expression in normal and malignant human intestine and effect on cultured human colonic adenocarcinoma cells. , 2002, European journal of internal medicine.
[28] T. Poggio,et al. Prediction of central nervous system embryonal tumour outcome based on gene expression , 2002, Nature.
[29] Hansotto Reiber,et al. Reporting Cerebrospinal Fluid Data: Knowledge Base and Interpretation Software , 2001, Clinical chemistry and laboratory medicine.
[30] G. Wright,et al. Proteinchip® surface enhanced laser desorption/ionization (SELDI) mass spectrometry: a novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures , 1999, Prostate Cancer and Prostatic Diseases.
[31] H. Reiber. External quality assessment in clinical neurochemistry: survey of analysis for cerebrospinal fluid (CSF) proteins based on CSF/serum quotients. , 1995, Clinical chemistry.
[32] A. Daluiski,et al. Evidence for linkage of the apolipoprotein A-II locus to plasma apolipoprotein A-II and free fatty acid levels in mice and humans. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[33] K. Kitagawa,et al. Polymorphism of apolipoprotein A-II (apoA-II) among inbred strains of mice. Relationship between the molecular type of apoA-II and mouse senile amyloidosis. , 1991, The Biochemical journal.
[34] J. Taylor,et al. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. , 1985, The Journal of clinical investigation.
[35] S. Edge,et al. Isoforms of apolipoprotein A-II in human plasma and thoracic duct lymph. Identification of proapolipoprotein A-II and sialic acid-containing isoforms. , 1985, The Journal of biological chemistry.
[36] G. Assmann,et al. Isoproteins of human apolipoprotein A-II: isolation and characterization. , 1983, Journal of lipid research.
[37] S. Ohman,et al. Principles of albumin and IgG analyses in neurological disorders. I. Establishment of reference values. , 1977, Scandinavian journal of clinical and laboratory investigation.
[38] G. Tibbling,et al. Principles of albumin and IgG analyses in neurological disorders. III. Evaluation of IgG synthesis within the central nervous system in multiple sclerosis. , 1977, Scandinavian journal of clinical and laboratory investigation.
[39] M. Dostál,et al. Levels of apolipoprotein A-II in cerebrospinal fluid in patients with neuroborreliosis are associated with lipophagocytosis , 2008, Folia Microbiologica.
[40] B. Adam,et al. Identification of patients with head and neck cancer using serum protein profiles. , 2004, Archives of otolaryngology--head & neck surgery.
[41] S. Weinberger,et al. Current developments in SELDI affinity technology. , 2004, Mass spectrometry reviews.
[42] Y. Benjamini,et al. Controlling the false discovery rate: a practical and powerful approach to multiple testing , 1995 .
[43] R. Cotter,et al. Mass Spectrometry , 1992, Bio/Technology.
[44] J. Freytag,et al. Clinical Chemistry , 1985, Analytical chemistry.
[45] E. Petricoin,et al. Use of proteomic patterns in serum to identify ovarian cancer , 2002, The Lancet.